IGFBP2表达评估idh突变的胶质瘤患者生存 （IGFBP2 expression predicts IDH-mutant glioma patient survival） ...

University of Virginia Health System, Department of Pathology, Division of Neuropathology, Box 800214, Charlottesville, VA 22908-0214, USA (T. D. Bourne). University of Virginia Health System ...

Low-grade gliomas are tumours that arise from the ... While patients can sometimes live with the tumours for years, those with IDH mutations tend to develop aggressive characteristics after ...

A similar effort would be welcomed in lower grade gliomas, particularly those with IDH1/IDH2mutation and 1p/19q codeletion, more vulnerable to treatment and therefore representing some kind of ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

Adults with diffuse gliomas who were undergoing tumor resection were eligible for inclusion. A total of 220 patients were included in the study, resulting in 767 IDH-mutant and 659 IDH-wild type ...

MUSK, a vision-language model, enhances cancer diagnosis by integrating multimodal data, outperforming existing methods in prognosis and treatment predictions.

In this particular case, the patient’s tumor contained a mutation, known as the IDH1. This mutation is acquired by chance and is known to improve overall survival. So the findings are particularly ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.